The suite will be equipped to fill vials with most highly-potent compounds, traditional small molecule drug and biologics, and DEA Schedule 1-5 compounds. It will offer liquid fill and lyophilization capabilities. Catalent provides sterile product development, advanced dose form and packaging technologies. Phase I capabilities in blow/fill/seal and in pre-filled syringes are currently available in the United States and France.
Source: Bioresearchonline.com
